Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.63 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.62 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.54 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9654592 | 0.85 | ALOX5 (0.60) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL9865792 | 0.85 | CYSLTR1 (0.56) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL9656181 | 0.83 | CYSLTR1 (0.60) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL12046916 | 0.82 | CYSLTR1 (0.77) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL9508040 | 0.80 | CYSLTR1 (0.60) | CYSLTR1CYSLTR2ADAMTS4 | |
| SCHEMBL9721967 | 0.80 | ALDH1A1 (0.59) | BCL2L1MCL1 | |
| SCHEMBL9876648 | 0.80 | CYSLTR2 (0.60) | CYSLTR1GPBAR1CYSLTR2ADAMTS4 | |
| SCHEMBL9022775 | 0.79 | CYSLTR1 (0.55) | CYSLTR1GPBAR1CYSLTR2 | |
| Hydrochloric Acid SCHEMBL6089058 | 0.79 | CYSLTR1 (0.55) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL9130463 | 0.78 | CYSLTR1 (1.00) | CYSLTR1GPBAR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0309541-B1 | SULFONYLCARBOXAMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-01-02 | — | — | EP | claimed |
| EP-0309541-A4 | SULFONYLCARBOXAMIDES. | AMERICAN HOME PROD (US) | 1989-07-24 | — | — | EP | claimed |
| EP-0309541-A1 | SULFONYLCARBOXAMIDES. | AMERICAN HOME PROD (US) | 1989-04-05 | — | — | EP | claimed |
| WO-1988006886-A1 | SULFONYLCARBOXAMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-09-22 | — | — | WO | claimed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| EP-0309541-B1 | SULFONYLCARBOXAMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | CYSLTR1 2842/4885GPBAR1 589/4885CYSLTR2 3511/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | CYSLTR1 3961/4885GPBAR1 470/4885CYSLTR2 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.